Edition:
India

Mesoblast Ltd (MESO.OQ)

MESO.OQ on NASDAQ Stock Exchange Global Select Market

5.77USD
10:07pm IST
Change (% chg)

$-0.02 (-0.35%)
Prev Close
$5.79
Open
$5.88
Day's High
$5.88
Day's Low
$5.73
Volume
2,681
Avg. Vol
10,056
52-wk High
$12.50
52-wk Low
$4.82

Latest Key Developments (Source: Significant Developments)

Mesoblast Gets Regenerative Medicine Advanced Therapy Designation From U.S. FDA​
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Mesoblast Ltd ::‍U.S. FDA GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR ITS MESENCHYMAL PRECURSOR CELL THERAPY ​.  Full Article

Mesoblast's Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Mesoblast Ltd ::MESOBLAST'S PHASE 3 TRIAL IN CHILDREN WITH ACUTE GRAFT VERSUS HOST DISEASE COMPLETES ENROLLMENT.MESOBLAST LTD - TOP-LINE RESULTS FROM PHASE 3 TRIAL ARE EXPECTED IN Q1 2018.  Full Article

Tigenix Announces Grant From Mesoblast Of Exclusive Global Patent License In Local Treatment Of Fistulae
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Tigenix Nv ::MESOBLAST GRANTS TIGENIX AN EXCLUSIVE GLOBAL PATENT LICENSE TO USE ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN THE LOCAL TREATMENT OF FISTULAE (EN).AGREEMENT INCLUDES RIGHT FOR CO TO GRANT SUB-LICENSES TO AFFILIATES AND THIRD PARTIES.MESOBLAST WILL RECEIVE SINGLE DIGIT ROYALTIES ON NET SALES OF CX601.MESOBLAST WILL RECEIVE UP TO EUR 20 MILLION IN PAYMENTS.  Full Article

Mesoblast Says Granted Tigenix Access To Certain Of Its Patents
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Mesoblast Ltd ::CO WILL RECEIVE UP TO EUR 20 MILLION IN PAYMENTS ​.‍HAS GRANTED TIGENIX EXCLUSIVE ACCESS TO CERTAIN OF ITS PATENTS TO SUPPORT GLOBAL COMMERCIALIZATION OF STEM CELL PRODUCT CX601​.  Full Article

Mesoblast says ‍qtrly loss attributable $7 mln
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Mesoblast Ltd ::‍Qtrly loss attributable $7 million versus loss of $19.8 million.Qtrly revenue $1.2 million versus $395,000‍​.  Full Article

MESOBLAST PHASE 2 TRIAL RESULTS SHOW DURABLE EFFECTS IN ARTHRITIS PATIENTS
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Mesoblast Ltd ::MESOBLAST PHASE 2 TRIAL RESULTS SHOW EARLY AND DURABLE EFFECTS OF SINGLE MESENCHYMAL PRECURSOR CELL INFUSION IN BIOLOGIC REFRACTORY RHEUMATOID ARTHRITIS PATIENTS.‍INFUSIONS WERE WELL-TOLERATED AND THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED DURING 52-WEEK PERIOD IN TRIAL​.  Full Article

Mesoblast appoints Bill Burns as vice chairman
Thursday, 1 Sep 2016 

Mesoblast Ltd :Mesoblast appoints Bill Burns as vice chairman Full Article

Mesoblast reports Q4 earnings per share $0.1278
Thursday, 25 Aug 2016 

Mesoblast Ltd : Mesoblast reports financial results and operational highlights for the three months and for the year ended 30 june 2016 .Q4 earnings per share $0.1278.  Full Article

Mesoblast provides update on global heart failure program
Tuesday, 14 Jun 2016 

: Mesoblast provides update on global heart failure program . Mesoblast says regains worldwide rights to cardiovascular field for its cell therapy platform; no financial consideration to teva pharmaceuticals . Aims to complete phase 3 heart failure trial within eighteen months . To meet program's remaining funding requirements, has been offered an equity finance facility . U.S. FDA approved use of second navigational catheter system in phase 3 program for advanced heart failure . Independent committee recommends continuation of heart failure trial without modification after data review of first 175 patients . Second trial of mpc-150-im almost 60% recruited; results are expected in second half of 2017 .Has unencumbered rights to partner with a cardiovascular co with commitment to heart failure product commercialization.  Full Article

Mesoblast says co received $6.2 mln from Australian government for R&D
Friday, 20 May 2016 

Mesoblast Ltd : Mesoblast receives $6.2 million from Australian government for research and development activities . Anticipates that it will continue to receive Australian government funds for ongoing research and development activities undertaken during FY 2016 .  Full Article

FDA to fast track Mesoblast's cell therapy for heart failure

Australian drug developer Mesoblast Ltd said on Thursday the U.S. Food and Drug Administration would fast track the review of its cell therapy treatment for heart failure patients under a new designation rolled out last December.